Synthesis of intracellular reduction-sensitive amphiphilic polyethyleneimine and poly(ε-caprolactone) graft copolymer for on-demand release of doxorubicin and p53 plasmid DNA

Acta Biomaterialia

Volumn 39, Issue , 2016, Pages 79-93

  Davoodi, Pooya ^a   Srinivasan, Madapusi P ^a   Wang, Chi Hwa ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Gene and drug co delivery; Graft copolymer; Redox cleavable linkage; Reduction sensitive; Smart drug delivery system

Indexed keywords

BIOCOMPATIBILITY; BIOMOLECULES; CELL CULTURE; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; CYTOTOXICITY; DISEASES; DNA; GENE THERAPY; GENE TRANSFER; GRAFT COPOLYMERS; GRAFTING (CHEMICAL); HYALURONIC ACID; NANOSYSTEMS; REDUCING AGENTS; REDUCTION; SULFUR COMPOUNDS; SYNTHESIS (CHEMICAL); TARGETED DRUG DELIVERY;

% REDUCTIONS; CO DELIVERIES; DISULFIDE LINKAGES; GENE AND DRUG CO-DELIVERY; GRAFT- COPOLYMERS; PLASMID DNA; POLY(ETHYLENEIMINE); REDOX-CLEAVABLE LINKAGE; REDUCTION-SENSITIVE; SMART DRUG DELIVERY SYSTEMS;

NANOPARTICLES;

CASPASE 3; COPOLYMER; CYSTAMINE; DOXORUBICIN; GLUTATHIONE; NANOPARTICLE; PLASMID DNA; POLYCAPROLACTONE; POLYETHYLENEIMINE; PROTEIN P53; DRUG CARRIER; POLYESTER; TP53 PROTEIN, HUMAN;

ARTICLE; BIOCOMPATIBILITY; CANCER CELL LINE; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; DISULFIDE BOND; DRUG CYTOTOXICITY; DRUG RELEASE; ENCAPSULATION; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; INFRARED SPECTROSCOPY; PARTICLE SIZE; POLYMERIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; THERMAL ANALYSIS; ZETA POTENTIAL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; GENE TRANSFER; GENETICS; HEP-G2 CELL LINE; METABOLISM; NEOPLASMS; PATHOLOGY; PHARMACOKINETICS; PHARMACOLOGY; PLASMID; RAT;

ANIMALS; DOXORUBICIN; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; HEP G2 CELLS; HUMANS; NEOPLASMS; PLASMIDS; POLYESTERS; POLYETHYLENEIMINE; RATS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84966534294     PISSN: 17427061     EISSN: 18787568     Source Type: Journal    
DOI: 10.1016/j.actbio.2016.05.003     Document Type: Article

References (51)

1. [1] Lowenstein, P.R., Why are we doing so much cancer gene therapy? Disentangling the scientific basis from the origins of gene therapy. Gene Ther. 4 (1997), 755–756.
2. [2] Cross, D., Burmester, J.K., Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 4 (2006), 218–227.
3. [3] Isner, J.M., Myocardial gene therapy. Nature 415 (2002), 234–239.
4. [4] Nordlie, M.A., Wold, L.E., Simkhovich, B.Z., Sesti, C., Kloner, R.A., Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy. J. Cardiovasc. Pharmacol. Ther. 11 (2006), 17–30.
5. [5] Baekelandt, V., De Strooper, B., Nuttin, B., Debyser, Z., Gene therapeutic strategies for neurodegenerative diseases. Curr. Opin. Mol. Ther. 2 (2000), 540–554.
6. [6] During, M.J., Leone, P., Adeno-associated virus vectors for gene therapy of neurodegenerative disorders. Clin. Neurosci. 3 (1995), 292–300.
7. [7] McMenamin, M.M., Wood, M.J., Progress and prospects: immunobiology of gene therapy for neurodegenerative disease: prospects and risks. Gene Ther. 17 (2010), 448–458.
8. [8] Bunnell, B.A., Morgan, R.A., Gene therapy for infectious diseases. Clin. Microbiol. Rev. 11 (1998), 42–56.
9. [9] Nijnik, A., Immunomodulatory approaches for prevention and treatment of infectious diseases. Curr. Opin. Microbiol. 16 (2013), 590–595.
10. [10] Verma, I.M., Somia, N., Gene therapy – promises, problems and prospects. Nature 389 (1997), 239–242.
11. [11] Davis, M.E., Zuckerman, J.E., Choi, C.H.J., Seligson, D., Tolcher, A., Alabi, C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464 (2010), 1067–1070.
12. [12] Chen, C.A., Lo, C.K., Lin, B.L., Sibley, E., Tang, S.C., Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma. Cancer Biol. Ther. 7 (2008), 303–309.
13. [13] Davoodi, P., Feng, F., Xu, Q., Yan, W.C., Tong, Y.W., Srinivasan, M.P., et al. Coaxial electrohydrodynamic atomization: microparticles for drug delivery applications. J. Control. Release 205 (2015), 70–82.
14. [14] Bao, X., Wang, W., Wang, C., Wang, Y., Zhou, J., Ding, Y., et al. A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy. Biomaterials 35 (2014), 8450–8466.
15. [15] Feng, Q., Yu, M.Z., Wang, J.C., Hou, W.J., Gao, L.Y., Ma, X.F., et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles. Biomaterials 35 (2014), 5028–5038.
16. [16] Meng, H., Mai, W.X., Zhang, H., Xue, M., Xia, T., Lin, S., et al. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo. ACS Nano 7 (2013), 994–1005.
17. [17] Ma, M., Yuan, Z.F., Chen, X.J., Li, F., Zhuo, R.X., A facile preparation of novel multifunctional vectors by non-covalent bonds for co-delivery of doxorubicin and gene. Acta Biomater. 8 (2012), 599–607.
18. [18] Xiong, X.-B., Binkhathlan, Z., Molavi, O., Lavasanifar, A., Amphiphilic block co-polymers: preparation and application in nanodrug and gene delivery. Acta Biomater. 8 (2012), 2017–2033.
19. [19] Vousden, K.H., Lu, X., Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002), 594–604.
20. [20] Vogelstein, B., Lane, D., Levine, A.J., Surfing the p53 network. Nature 408 (2000), 307–310.
21. [21] Hainaut, P., Hollstein, M., P53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77 (2000), 81–137.
22. [22] Fridman, J.S., Lowe, S.W., Control of apoptosis by p53. Oncogene 22 (2003), 9030–9040.
23. [23] Vassilev, L.T., MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13 (2007), 23–31.
24. [24] DeLeo, A.B., Jay, G., Appella, E., Dubois, G.C., Law, L.W., Old, L.J., Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. U.S.A. 76 (1979), 2420–2424.
25. [25] Alshamsan, A., Haddadi, A., Incani, V., Samuel, J., Lavasanifar, A., Uludag, H., Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine. Mol. Pharm. 6 (2009), 121–133.
26. [26] Gosselin, M.A., Guo, W., Lee, R.J., Efficient gene transfer using reversibly cross-linked low molecular weight polyethylenimine. Bioconjug. Chem. 12 (2001), 989–994.
27. [27] Ping, Y., Liu, C., Zhang, Z., Liu, K.L., Chen, J., Li, J., Chitosan-graft-(PEI-beta-cyclodextrin) copolymers and their supramolecular PEGylation for DNA and siRNA delivery. Biomaterials 32 (2011), 8328–8341.
28. [28] Yang, C., Li, H., Goh, S.H., Li, J., Cationic star polymers consisting of alpha-cyclodextrin core and oligoethylenimine arms as nonviral gene delivery vectors. Biomaterials 28 (2007), 3245–3254.
29. [29] Liu, J., Huang, Y., Kumar, A., Tan, A., Jin, S., Mozhi, A., et al. PH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 32 (2014), 693–710.
30. [30] Saito, G., Swanson, J.A., Lee, K.-D., Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55 (2003), 199–215.
31. [31] Jhaveri, A., Deshpande, P., Torchilin, V., Stimuli-sensitive nanopreparations for combination cancer therapy. J. Control. Release 190 (2014), 352–370.
32. [32] Fleige, E., Quadir, M.A., Haag, R., Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev. 64 (2012), 866–884.
33. [33] Sun, H., Meng, F., Cheng, R., Deng, C., Zhong, Z., Reduction and pH dual-bioresponsive crosslinked polymersomes for efficient intracellular delivery of proteins and potent induction of cancer cell apoptosis. Acta Biomater. 10 (2014), 2159–2168.
34. [34] Liu, J., Xu, Y., Yang, Q., Li, C., Hennink, W.E., Zhuo, R., et al. Reduction biodegradable brushed PDMAEMA derivatives synthesized by atom transfer radical polymerization and click chemistry for gene delivery. Acta Biomater. 9 (2013), 7758–7766.
35. [35] Deng, H., Zhang, Y., Wang, X., Jianhuazhang, Cao.Y., Liu, J., et al. Balancing the stability and drug release of polymer micelles by the coordination of dual-sensitive cleavable bonds in cross-linked core. Acta Biomater. 11 (2015), 126–136.
36. [36] Lin, D., Jiang, Q., Cheng, Q., Huang, Y., Huang, P., Han, S., et al. Polycation-detachable nanoparticles self-assembled from mPEG-PCL-g-SS-PDMAEMA for in vitro and in vivo siRNA delivery. Acta Biomater. 9 (2013), 7746–7757.
37. [37] Meng, F., Hennink, W.E., Zhong, Z., Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 30 (2009), 2180–2198.
38. [38] Hwang, C., Sinskey, A.J., Lodish, H.F., Oxidized redox state of glutathione in the endoplasmic reticulum. Science 257 (1992), 1496–1502.
39. [39] Hong, R., Han, G., Fernández, J.M., Kim, B.-J., Forbes, N.S., Rotello, V.M., Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J. Am. Chem. Soc. 128 (2006), 1078–1079.
40. [40] Kuppusamy, P., Li, H., Ilangovan, G., Cardounel, A.J., Zweier, J.L., Yamada, K., et al. Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. Cancer Res. 62 (2002), 307–312.
41. [41] Song, N., Ding, M., Pan, Z., Li, J., Zhou, L., Tan, H., et al. Construction of targeting-clickable and tumor-cleavable polyurethane nanomicelles for multifunctional intracellular drug delivery. Biomacromolecules 14 (2013), 4407–4419.
42. [42] Li, H., Jiang, H., Zhao, M., Fu, Y., Sun, X., Intracellular redox potential-responsive micelles based on polyethylenimine-cystamine-poly([varepsilon]-caprolactone) block copolymer for enhanced miR-34a delivery. Polym. Chem. 6 (2015), 1952–1960.
43. [43] Zhu, X.H., Gan, S.K., Wang, C.H., Tong, Y.W., Proteins combination on PHBV microsphere scaffold to regulate Hep3B cells activity and functionality: a model of liver tissue engineering system. J. Biomed. Mater. Res. A 83 (2007), 606–616.
44. [44] Sato, Y., Takasu, A., Conversion of diols to dithiols via a dehydration polycondensation with a dicarboxylic acid containing a disulfide and subsequent reduction. Polym. J. 42 (2010), 956–959.
45. [45] Hu, C.-H., Zhang, X.-Z., Zhang, L., Xu, X.-D., Zhuo, R.-X., Temperature- and pH-sensitive hydrogels to immobilize heparin-modified PEI/DNA complexes for sustained gene delivery. J. Mater. Chem. 19 (2009), 8982–8989.
46. [46] Liu, L., Zheng, M., Renette, T., Kissel, T., Modular synthesis of folate conjugated ternary copolymers: polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate for targeted gene delivery. Bioconjug. Chem. 23 (2012), 1211–1220.
47. [47] Arote, R., Kim, T.H., Kim, Y.K., Hwang, S.K., Jiang, H.L., Song, H.H., et al. A biodegradable poly(ester amine) based on polycaprolactone and polyethylenimine as a gene carrier. Biomaterials 28 (2007), 735–744.
48. [48] Chen, W., Zou, Y., Meng, F., Cheng, R., Deng, C., Feijen, J., et al. Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs. Biomacromolecules 15 (2014), 900–907.
49. [49] Zhao, F., Yin, H., Zhang, Z., Li, J., Folic acid modified cationic gamma-cyclodextrin-oligoethylenimine star polymer with bioreducible disulfide linker for efficient targeted gene delivery. Biomacromolecules 14 (2013), 476–484.
50. [50] Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U.S.A. 92 (1995), 7297–7301.
51. [51] Hillaireau, H., Couvreur, P., Nanocarriers’ entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66 (2009), 2873–2896.